NEWS

• Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA) to strengthen preparedness and rapid response capabilities for influenza pandemics
• Agreement includes provision for Seqirus to provide BARDA with supply of AUDENZ, the first-ever FDA-approved adjuvanted, cell-based pandemic influenza vaccine, which was developed in partnership with BARDA

New facility in Waltham, Massachusetts, will support CSL’s growing R&D portfolio, including the self-amplifying mRNA technology platform, the next generation of mRNA vaccine technology, for seasonal and pandemic influenza vaccines.

• The FDA has granted approval of multi-dose vial presentation for AUDENZ™ to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.
• As the first-ever adjuvanted, cell-based influenza vaccine, AUDENZ™ was originally approved by the FDA in February 2020 in prefilled syringe presentation.
• This approval marks an important milestone in the company’s pandemic preparedness efforts in partnership with Biomedical Advanced Research and Development Authority (BARDA).

• Approval aligns with universal age recommendation for all eligible people six months and older to receive annual influenza vaccination 1
• Cell-based influenza vaccines are designed to produce an exact match to the World Health Organization (WHO)-selected influenza virus strains 2,3
• This approval reinforces the value of this innovative influenza vaccine technology as part of Seqirus’ mission to help protect as many eligible people as possible against influenza, especially in light of the ongoing COVID-19 pandemic

• Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives
• Company will utilize its combination of cell-based and adjuvanted influenza vaccine technologies, as well as its next-generation self-amplifying mRNA platform
• Multi-year contract with Biomedical Advanced Research and Development Authority (BARDA) builds on longstanding, successful public-private partnership to provide rapid vaccine manufacturing response in an influenza pandemic

• Appoints Roberta Duncan as new program lead to drive technology advancement
• Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza

Findings from a new observational safety study conducted in the U.S. found no unexpected adverse pregnancy outcomes in pregnant people who were vaccinated with the cell-based quadrivalent seasonal influenza vaccine during pregnancy.

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic.

Company announces the publication of new real-world evidence on effectiveness of the MF59® adjuvanted, trivalent influenza vaccine (aTIV).